Dupilumab, the first approved biological agent for the treatment of AD, which acts by blocking IL-4Rα and thus the activity of both IL-4 and IL-13, demonstrated the effectiveness of blocking type 2 cytokines, their receptors, or their intracellular signal transducers JAK/STAT pathway (8, 59–61). The gene discussed is SOAT1; the disease is Alzheimer disease.